Entrada Therapeutics utilizes a proprietary Endosomal Escape Vehicle platform to develop intracellular therapeutics. The EEV platform allows therapeutics to enter cells with broad distribution and deep tissue penetration by utilizing cellular endocytic mechanisms. The platform is also designed to increase the proportion of therapeutics that are released from the early endosome, another hurdle facing intracellular therapeutics.
Entrada is currently developing oligonucleotide, antibody, and enzyme-based therapeutics for the treatment of Duchenne Muscular Dystrophy and other neuromuscular diseases, neurodegenerative diseases, inflammatory diseases, solid tumors, and Mitochondrial Neurogastrointestinal Encephalomyopathy. Therapeutics are currently in discovery and preclinical phases.
Claim company profile to post jobs directly on this page and this website.